Treatment with this SCFA inhibited cancer cell growth by driving metabolic rewiring and epigenetic reprogramming, involving a decrease in NRF2, an increase in the NRF2 negative regulator Keap1, and inhibition of NRF2-target genes, such as as NQO1. This evidence concerns the gene KEAP1 and cancer.